![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by jrbecker on July 10, 2003, at 12:57:18
It looks like some pharm company is trying to bring a new drug containing an active metabolite of Effexor to the market. Currently being called DVS-233 SR, it is in Phase III for depression.
I'm not sure if this is Wyeth (Effexor's manuf.) or another company that's testing the drug. It could be one way Wyeth's plans to extend its share of the market once Effexor goes generic in 2007 (a la Lexapro succeeding Celexa, Focalin succeeding Ritalin). Or maybe Wyeth is leasing the metabolite out to another pharm company.
Supposedly, anybody that has taken Effexor within 90 days is excluded from the study. Whether you have and you decide to share that information with them, well, that's up to you.
Go to http://www.centerwatch.com and search by "DVS-233 " if you would like to participate, to see if there is a test site near you.
The locations I was able to find were: Santa Monica, CA; Newport Beach, CA; Orange, CA; Wheat Ridge, CO; New Britain, CT; Winter Park, FL; St. Petersburg, FL; Chicago, IL; Okemos, MI; Omaha, NE; Moorestown, NJ; New York, NY; Havertown, PA; Dallas, TX; Austin, TX; Washington, DC
http://www.centerwatch.com/search.asp?FreeText=off&qu=dvs-233
Posted by djmmm on July 10, 2003, at 14:06:00
In reply to Effexor metabolite in Phase III testing, posted by jrbecker on July 10, 2003, at 12:57:18
> It looks like some pharm company is trying to bring a new drug containing an active metabolite of Effexor to the market. Currently being called DVS-233 SR, it is in Phase III for depression.
>
> I'm not sure if this is Wyeth (Effexor's manuf.) or another company that's testing the drug. It could be one way Wyeth's plans to extend its share of the market once Effexor goes generic in 2007 (a la Lexapro succeeding Celexa, Focalin succeeding Ritalin). Or maybe Wyeth is leasing the metabolite out to another pharm company.
>
> Supposedly, anybody that has taken Effexor within 90 days is excluded from the study. Whether you have and you decide to share that information with them, well, that's up to you.
>
> Go to http://www.centerwatch.com and search by "DVS-233 " if you would like to participate, to see if there is a test site near you.
>
> The locations I was able to find were: Santa Monica, CA; Newport Beach, CA; Orange, CA; Wheat Ridge, CO; New Britain, CT; Winter Park, FL; St. Petersburg, FL; Chicago, IL; Okemos, MI; Omaha, NE; Moorestown, NJ; New York, NY; Havertown, PA; Dallas, TX; Austin, TX; Washington, DC
>
> http://www.centerwatch.com/search.asp?FreeText=off&qu=dvs-233
>
>I heard about this, it's desvenlafaxine (O-desmethylvenlafaxine) it is slightly more potent than the parent drug, and it's half life is about 10 hours compared to venlafaxine's 4 hour half-life. Now they can sell DSV233-SR as a once daily version of effexor (I'm assuming the "SR" part of the code designation is "slow-release")
Posted by stjames on July 10, 2003, at 14:45:28
In reply to Re: Effexor metabolite in Phase III testing, posted by djmmm on July 10, 2003, at 14:06:00
> I heard about this, it's desvenlafaxine (O-desmethylvenlafaxine) it is slightly more potent than the parent drug, and it's half life is about 10 hours compared to venlafaxine's 4 hour half-life.
This would be a very useful "least patentable difference". I wonder the effect of taking just one active vs many actives (from the parent) &
if there is any synergy between the actives
Posted by djmmm on July 10, 2003, at 15:23:28
In reply to Re: Effexor metabolite in Phase III testing, posted by stjames on July 10, 2003, at 14:45:28
> > I heard about this, it's desvenlafaxine (O-desmethylvenlafaxine) it is slightly more potent than the parent drug, and it's half life is about 10 hours compared to venlafaxine's 4 hour half-life.
>
> This would be a very useful "least patentable difference". I wonder the effect of taking just one active vs many actives (from the parent) &
> if there is any synergy between the activesI think they singled out the O-desmethylvenlafaxine metabolite because the N-desmethyl and N,O,-didesmethyl metabolites are less active (not as potent) as the parent drug
Posted by SLS on July 10, 2003, at 16:16:16
In reply to Re: Effexor metabolite in Phase III testing, posted by djmmm on July 10, 2003, at 15:23:28
> I think they singled out the O-desmethylvenlafaxine metabolite because the N-desmethyl and N,O,-didesmethyl metabolites are less active (not as potent) as the parent drugDo you know if the ratio of potency for 5-HT versus NE reuptake inhibition is closer to 1:1?
- Scott
Posted by djmmm on July 12, 2003, at 16:12:18
In reply to Re: Effexor metabolite in Phase III testing, posted by SLS on July 10, 2003, at 16:16:16
>
> > I think they singled out the O-desmethylvenlafaxine metabolite because the N-desmethyl and N,O,-didesmethyl metabolites are less active (not as potent) as the parent drug
>
> Do you know if the ratio of potency for 5-HT versus NE reuptake inhibition is closer to 1:1?
>
>
> - ScottNot likely...since the active metabolite version is only slightly (if you can even call it slightly) more potent than the parent drug..I think I read it's like .3 times as potent (Yes, that's POINT 3)....I don't know how that number would reflect any improvement over the partent drug....I think it has more to do with the extended half life then anything else. But who knows. I think were are only seeing this med because of duloxetine (which is more potent, and has a closer 5-ht/NE ratio)
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.